论文部分内容阅读
目的:探讨孟鲁司特钠佐治呼吸道合胞病毒毛细支气管炎的临床疗效及安全性。方法:将123例呼吸道合胞病毒毛细支气管炎患儿按随机数表法分为两组,对照组61例给予综合治疗,治疗组62例在综合治疗基础上加用孟鲁司特钠4mg/d,每晚睡前口服,持续4周后停药。考察患儿咳嗽消失时间、喘息消失时间、氧疗时间、雾化次数和住院时间;随访1年,记录患儿喘息复发情况。结果:治疗组患儿咳嗽消失时间、喘息消失时间、氧疗时间和平均住院时间明显短于对照组,雾化次数明显少于对照组,1年内喘息复发率为15.79%,明显低于对照组的26.36%,两组比较差异均有统计学意义(P<0.01);用药期间未见明显不良反应。结论:孟鲁司特钠佐治呼吸道合胞病毒毛细支气管炎安全有效,连用4周,可降低喘息复发率,改善预后,值得临床推广应用。
Objective: To investigate the clinical efficacy and safety of montelukast sodium in treating respiratory syncytial virus bronchiolitis. Methods: 123 cases of children with respiratory syncytial virus bronchiolitis were divided into two groups according to random number table method, the control group of 61 patients given comprehensive treatment, the treatment group of 62 patients on the basis of comprehensive treatment plus montelukast sodium 4mg / d, orally every night before going to bed, after 4 weeks of withdrawal. Children with cough disappear time, wheezing disappeared, oxygen therapy time, the number of atomization and hospital stay; follow-up of 1 year, record the recurrence of wheezing in children. Results: The cough disappear time, wheezing disappearing time, oxygen therapy time and average length of hospital stay in treatment group were significantly shorter than those in control group, and the number of atomization was significantly less than that in control group. The recurrence rate of wheezing in one year was 15.79%, which was significantly lower than that in control group (26.36%). The differences between the two groups were statistically significant (P <0.01). No obvious adverse reactions were observed during the treatment. Conclusion: Montelukast sodium adjuvant respiratory syncytial virus bronchiolitis is safe and effective for 4 weeks, can reduce the recurrence rate of wheezing and improve the prognosis, it is worthy of clinical application.